Intervention study to evaluate the efficacy of etelcalcetide and cinacalcet on bone and mineral disorders in hemodialysis patient.

Intervention study to evaluate the efficacy of etelcalcetide and cinacalcet on bone and mineral disorders in hemodialysis patient. - Study to evaluate the efficacy of eterlcalcetide and cinacalcet on bone and mineral disorders in hemodialysis patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029155

Enrollment

Registered

2017-10-08

Start date

2017-10-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis patients treated with cinacalcet for secondary hyperparathyroidism

Interventions

etelcalcetide dosge(1.25-15mg/ever hemodialysis session) 12 weeks cinacalcet dosage (12.5-100mg/day) 12weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patient who taken cinacalcet(25mg or 50mg) with serum adjusted calcium more than 9mg/dl, serum phosphate less than 7mg/dl and intact parathyroid hormone levels more than 60pg/ml and less than 240pg/ml

Exclusion criteria

Exclusion criteria: The patient judged low adherence was and additionally.

Design outcomes

Primary

Measure	Time frame
The rate of change of the parathyroid hormone in after fore weeks. Dosage of etelcalcetide.	—

Countries

Japan

Contacts

Public ContactMakoto Toguchi

Kawashima hospital urology

toguchimakoto@gmail.com088-631-0110

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026